Clinical trials are much of the basis for the practice of medicine. Funding of trials has dramatically shifted so that today, trials paid for by pharmaceutical and device makers outnumber publicly funded trials 6-to-1. Some studies indicate this makes bias in trials more likely, jeopardizing public health. Experts discuss.
Guest Information:
- Jocelyn Ullrich, Assistant Vice President of Science and Regulatory Advocacy, Pharmaceutical Research and Manufacturers of America (PhRMA)
- Dr. John Abramson, Lecturer in Healthcare Policy, Harvard Medical School
- Dr. Joel Lexchin, emergency medicine physician and Professor of Health Policy, York University
Leave a Reply